Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services

CAR-T Digest - August 2020

Weekly Digest - June 2025

11 June 2025: Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services

Simtra BioPharma Solutions and MilliporeSigma (Merck KGaA’s Life Science business) have entered a five-year strategic alliance to streamline ADC manufacturing and bioconjugation services
This partnership aims to reduce development complexity and timelines for biopharma companies by offering a seamless, end-to-end solution from linker/payload production to fill-finish
The ADC market is rapidly expanding, projected to grow from $1.79 billion today to $7 billion by 2035, with CDMOs currently producing over 70% of these therapeutics
With over 200 ADCs in clinical trials, the alliance focuses on accelerating drug development and delivery to patients by minimizing risks and improving process efficiency